Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 13/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | EBP | Q15125 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.40 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5852077 | 0.86 | ESR1 (0.52) | ESR1EBPSIGMAR1ESR2HRH3 | |
| SCHEMBL5851836 | 0.85 | ESR1 (0.52) | ESR1HDAC1HDAC2EBPSIGMAR1 | |
| SCHEMBL5851849 | 0.83 | ESR1 (0.55) | ESR1EBPSIGMAR1ESR2HRH3 | |
| SCHEMBL5852021 | 0.82 | ESR1 (0.45) | ESR1HDAC1HDAC2EBPSIGMAR1 | |
| SCHEMBL5851981 | 0.81 | ESR1 (0.53) | ESR1EBPSIGMAR1ESR2HRH3 | |
| SCHEMBL8642477 | 0.79 | ESR1 (0.47) | ESR1HDAC1HDAC2ESR2PLA2G4B | |
| SCHEMBL5853779 | 0.78 | ESR1 (0.47) | ESR1HDAC1HDAC2EBPSIGMAR1 | |
| SCHEMBL5852960 | 0.78 | ESR1 (0.56) | ESR1EBPSIGMAR1ESR2 | |
| SCHEMBL5851502 | 0.78 | ESR1 (0.56) | ESR1EBPSIGMAR1ESR2 | |
| SCHEMBL5851975 | 0.77 | ESR1 (0.65) | ESR1EBPSIGMAR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878750-B2 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2005-04-12 | — | — | US | claimed |
| EP-1098874-B1 | BENZOCYCLOHEPTENES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS, AND THEIR USE FOR PRODUCING MEDICAMENTS | SCHERING AG (DE) | 2003-06-18 | — | — | EP | claimed |
| US-20030050324-A1 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2003-03-13 | — | — | US | claimed |
| US-6495607-B2 | 8,9-DIHYDRO-7H-BENZOCYCLOHEPTENE DERIVATIVES ARE USEFUL FOR PHOPHYLAXIS AND THERAPY OF OSTEOPOROSIS(HAVE SELECTIVE ESTROGENIC ACTIVITY ON BONES) | SCHERING AG (DE) | 2002-12-17 | — | — | US | claimed |
| US-20020068765-A1 | BENZOCYCLOHEPTENES, PROCESS FOR THEIR PRODUCTION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THE LATTER AS WELL AS THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-06-06 | — | — | US | claimed |
| US-7145015-B2 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain that latter as well as their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2006-12-05 | — | — | US | disclosed |
| EP-1165061-B1 | USE OF COMPOUND PREPARATION MADE OF VITAMIN D METABOLITES OR VITAMIN D ANALOGUES AND PARTIAL ESTROGEN AGONISTS FOR TREATING OSTEOPOROSIS | SCHERING AG (DE) | 2005-10-19 | — | — | EP | disclosed |
| US-20050182081-A1 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-08-18 | — | — | US | disclosed |
| US-6878750-B2 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2005-04-12 | — | — | US | disclosed |
| EP-1098874-B1 | BENZOCYCLOHEPTENES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS, AND THEIR USE FOR PRODUCING MEDICAMENTS | SCHERING AG (DE) | 2003-06-18 | — | — | EP | disclosed |
| US-20030050324-A1 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2003-03-13 | — | — | US | disclosed |
| US-6495607-B2 | 8,9-DIHYDRO-7H-BENZOCYCLOHEPTENE DERIVATIVES ARE USEFUL FOR PHOPHYLAXIS AND THERAPY OF OSTEOPOROSIS(HAVE SELECTIVE ESTROGENIC ACTIVITY ON BONES) | SCHERING AG (DE) | 2002-12-17 | — | — | US | disclosed |
| US-20020068765-A1 | BENZOCYCLOHEPTENES, PROCESS FOR THEIR PRODUCTION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THE LATTER AS WELL AS THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-06-06 | — | — | US | disclosed |
| EP-1165061-A2 | COMPOUND PREPARATION MADE OF VITAMIN D METABOLITES OR VITAMIN D ANALOGUES AND AN OESTROGENIC COMPONENT FOR TREATING OSTEOPOROSIS | Schering Aktiengesellschaft (DE) | 2002-01-02 | — | — | EP | disclosed |
| EP-1098874-A1 | BENZOCYCLOHEPTENES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS, AND THEIR USE FOR PRODUCING MEDICAMENTS | Schering Aktiengesellschaft (DE) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000061123-A2 | COMPOUND PREPARATION MADE OF VITAMIN D METABOLITES OR VITAMIN D ANALOGUES AND AN OESTROGENIC COMPONENT FOR TREATING OSTEOPOROSIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-10-19 | — | — | WO | disclosed |
| WO-2000003979-A1 | BENZOCYCLOHEPTENES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS, AND THEIR USE FOR PRODUCING MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068765-A1 | BENZOCYCLOHEPTENES, PROCESS FOR THEIR PRODUCTION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THE LATTER AS WELL AS THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS | CYP19A1, ESRRA, SULT2A1 | ESR1 36/4885HDAC1 1925/4885HDAC2 1311/4885 |
| US-20050182081-A1 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | CYP19A1, ESR2, ESRRA | ESR1 8/4885HDAC1 1774/4885HDAC2 1476/4885 |
| US-20030050324-A1 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | CYP19A1, ESRRA, SULT2A1 | ESR1 36/4885HDAC1 1925/4885HDAC2 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.